Antibody-drug conjugates (ADCs) constitute a rapidly evolving class of targeted oncology therapeutics that couple tumor-selective antibodies with highly potent cytotoxins. At the 16th Annual World ADC ...

Antibody-drug conjugates (ADCs) continue to reshape the oncology landscape by combining the target specificity of monoclonal antibodies (mAbs) with the potent cytotoxicity of small-molecule drugs.

Over the last several decades, mounting interest has positioned bioconjugate therapeutics as one of the most promising biopharmaceutical modalities. Work in chemical biology, including novel ...

The emergence of antibody-drug conjugates (ADCs) has seen them become a promising class of anticancer therapeutics, exhibiting better precision and reduced off-target toxicity in targeting cancer ...

Grace Liu (left) is a Technical Account Manager at Sino Biological US Inc. (PA, USA). Grace joined Sino Biological in 2022, supporting CRO services and project management in the western and central US ...

While chemotherapy is a very commonly used cancer therapy, it frequently causes serious side effects. Antibody-drug conjugates (ADCs) are a promising emerging cancer therapy that combines the ...

Chemotherapy is one of the most widely used cancer therapies; however, chemotherapy often causes serious side effects. Antibody-drug conjugates (ADCs) are promising emergent cancer therapies that ...